Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week.

Trial Profile

Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2013

At a glance

  • Drugs Trabedersen (Primary) ; Lomustine; Procarbazine; Temozolomide; Vincristine
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Sponsors Isarna Therapeutics; Sirna Therapeutics
  • Most Recent Events

    • 21 Apr 2010 Results presented at the 101st Annual Meeting of the American Association for Cancer Research
    • 17 Dec 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 20 Sep 2009 Results reported at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology (ECCO/ESMO 2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top